Abstract
Awareness, proper diagnosis and treatment of cardiac amyloidosis have increased, but there are still several unmet needs that have to be addressed for the optimal care of the disease. In this comprehensive review, we describe current and future treatments for both hereditary and wild-type TTR cardiac amyloidosis and also review lifestyle, including current challenges and opportunities for specific dietary concerns and exercise sports for these patients.
Keywords:
cardiac amyloidosis; cardiomyopathy; disease-modifying agents; heart failure; small interfering RNA.
MeSH terms
-
Amyloid Neuropathies, Familial* / diagnosis
-
Amyloid Neuropathies, Familial* / genetics
-
Amyloid Neuropathies, Familial* / physiopathology
-
Amyloid Neuropathies, Familial* / therapy
-
Cardiomyopathies* / genetics
-
Cardiomyopathies* / physiopathology
-
Cardiomyopathies* / therapy
-
Cardiovascular Agents / adverse effects
-
Cardiovascular Agents / therapeutic use
-
Exercise Therapy
-
Exercise*
-
Genetic Predisposition to Disease
-
Humans
-
Prealbumin
-
Risk Reduction Behavior
-
Treatment Outcome
Substances
-
TTR protein, human
-
Cardiovascular Agents
-
Prealbumin
Supplementary concepts
-
Amyloidosis, Hereditary, Transthyretin-Related